With the start of a new week comes excitement surrounding a new set of companies looking to make an impact through their public offerings. According to Benzinga Pro, these alluring companies are expected to go into public trading this week.
- Third Harmonic Bio, Inc. THRD will be publicly traded beginning September 15, 2022. The company’s price range is set between $16 and $18 with an insider lock-in period of 180 days. Third Harmonic Bio, Inc. will offer 9,000,000 shares at a per share value of $17.
- Corebridge Financial, Inc. CRBG becomes publicly listed from September 15, 2022. The company has a fixed price range between $21 and $24 with a lock-up period of 180 days. Corebridge Financial, Inc. will offer 80,000,000 shares at a per share value of $22.50.
- Jupiter Neurosciences, Inc. JUNS will be publicly traded beginning September 14, 2022. The company’s price range is set between $5 and $7 with an insider lock-in period of 180 days. Jupiter Neurosciences, Inc. will offer 2,500,000 shares at a value per share of $6.
- Lichen China Limited LICN will be publicly traded from September 12, 2022. Lichen China Limited will offer 6,250,000 shares at a per share value of $4 with an insider lock-up period of 180 days.
Valuation of IPOs
Initial public offerings, or IPOs, are the transition processes of private companies deciding to go public and offer stock to investors on the stock exchange. IPOs generally offer companies the opportunity to build capital by distributing shares in the market. A company wishing to go public must first meet SEC requirements and work with investment banks through audits to determine pricing, date of offering and other important data points. before the offer.
Firms and investment banks will work to establish a price range between which the stock should sell. This is called a range of offers. Once a company goes public, its stock comes with an opening price. The insider lock-in period is usually a set number of days after an IPO, where insiders of the company, or employees with a 10% or more stake in their company, cannot sell shares.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.